Skip to main content

Table 1 Characteristics of study population and by outcomes of interests; SARS-CoV-2 infections, hospitalisation, intensive care unit (ICU) admission, and death in Norway, 15 July–30 November 2021

From: Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

   Total study population SARS-CoV-2 infection Hospitalisation ICU admission COVID-19 deaths
n % n % n % n % n %
All - 4,301,995 - 74,371 - 1429 - 290 - 331 -
Age groups 18–24 years 457,238 10.6 11,499 15.5 24 1.7 1 0.3 0 0.0
  25–34 years 747,249 17.4 16,013 21.5 113 7.9 16 5.5 2 0.6
  35–44 years 705,460 16.4 17,131 23.0 190 13.3 40 13.8 2 0.6
  45–54 years 735,420 17.1 14,050 18.9 206 14.4 46 15.9 6 1.8
  55–64 years 653,259 15.2 7440 10.0 202 14.1 63 21.7 22 6.6
  65–74 years 540,898 12.6 4604 6.2 214 15.0 52 17.9 38 11.5
  75–84 years 335,628 7.8 2557 3.4 301 21.1 59 20.3 103 31.1
  ≥ 85 years 126,843 2.9 1077 1.4 179 12.5 13 4.5 158 47.7
Sex Male 2,160,307 50.2 37,098 49.9 791 55.4 196 67.6 185 55.9
  Female 2,141,688 49.8 37,273 50.1 638 44.6 94 32.4 146 44.1
Underlying conditions No risk group 3,401,381 79.1 62,802 84.4 711 49.8 129 44.5 78 23.6
  Medium risk 788,954 18.3 10,247 13.8 524 36.7 115 39.7 180 54.4
  High risk 111,660 2.6 1322 1.8 194 13.6 46 15.9 73 22.1
Country of birth Norway 3202,876 74.5 46,501 62.5 791 55.4 170 58.6 247 74.6
  Outside Norway 802,615 18.7 25,579 34.4 506 35.4 103 35.5 34 10.3
  Unknown 296,504 6.9 2291 3.1 132 9.2 17 5.9 50 15.1
Crowding Yes 336,777 7.8 11,953 16.1 175 12.2 29 10.0 7 2.1
  No 3,728,263 86.7 57,206 76.9 1154 80.8 238 82.1 299 90.3
  Unknown 236,955 5.5 5212 7.0 100 7.0 23 7.9 25 7.6